Anthracycline-induced cardiotoxicity: A case report and review of literature.

ABSTRACT:

Background

Doxorubicin and other anthracycline derivatives inhibit topoisomerase II and is an important class of cytotoxic chemotherapy in cancer treatment. The use of anthracycline is limited by dose-dependent cardiotoxicity, which may manifest initially as asymptomatic cardiac dysfunction with subsequent progression to congestive heart failure. Despite baseline assessment and periodic monitoring of cardiac function for patients receiving anthracycline agents, there are unmet needs in prediction and prevention of anthracycline-induced cardiotoxicity (AIC).

Case summary

A 35-year-old African American female was found to have a 9-cm high-grade osteosarcoma of right femur and normal baseline cardiac function with left ventricular ejection fraction of approximately 60%-70% dete

SUBMITTER: Chong EG 

PROVIDER: S-EPMC7821007 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature